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ABSTRACT
A retrospective survey of candidaemia between 2001 and 2006 was performed at the University Hospital
of Vienna, a 2200-bed centre with large organ transplantation and haematology–oncology units. The
incidence rate of Candida spp. in blood cultures increased from 0.27 cases ⁄ 1000 admissions in 2001 to
0.77 cases ⁄ 1000 admissions in 2006 (p <0.005). The incidence of candidaemia caused by Candida albicans
and by non-albicans Candida spp. both increased during this period; although there was a trend towards
an increased incidence (37%) of non-albicans Candida spp., particularly Candida glabrata, in surgical
wards, C. albicans remained the predominant pathogen (63%). In the haematology–oncology unit,
C. albicans remained the leading pathogen (23 ⁄ 29 isolates, 79%), followed by Candida tropicalis and
C. glabrata (2 ⁄ 29, 7% each), Candida sake and Candida lusitaniae (1 ⁄ 29, 3% each). The overall survival rate
was 43.8%, ranging from 32.8% in 2004 to 63.6% in 2002. In total, 108 (33.2%) patients died within
4 weeks of the ﬁrst isolation of Candida spp. from blood; 58 (54%) of these patients died within the ﬁrst
7 days, and a further 34 patients died within the next 3 months. Fluconazole was used extensively
(24 701.5 deﬁned daily doses), followed by amphotericin B (8981.4 deﬁned daily doses), during 2005.
The consumption of antifungal agents increased continuously (p <0.05) because of increased use of
voriconazole and caspofungin. Although the numbers of susceptible patients remained unchanged, the
net increase in the number of cases of candidaemia warrants a re-evaluation of the risk-factors and the
use of improved diagnostic procedures for invasive fungal infections.
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INTRODUCTION
Invasive fungal infections, particularly invasive
Candida infections, are recognised increasingly as
a primary cause of morbidity and mortality in
immunocompromised and severely-ill patients
[1,2]. Candidaemia is present in c. 50% of cases,
and this remains the only marker for invasive
Candida infection used in epidemiological studies.
While studies in the USA have revealed an
association between candidaemia and the number
of hospital beds and ⁄ or an academic afﬁliation
[3], European studies have shown a widely
varying incidence of invasive fungal infections
in special centres, patient groups and countries
[4–8]. Candida albicans is responsible for
most invasive Candida infections [7–10], but a
substantial shift towards dose-dependent azole-
susceptible, or even intrinsically azole-resistant,
non-albicans Candida spp., e.g., Candida glabrata
and Candida krusei, has been observed in some
studies [6,11–13]. However, while a Dutch study
reported a two-fold increase in the incidence of
candidaemia, with a shift towards non-albicans
Candida spp., studies in Switzerland and Norway
have reported an unchanged incidence of
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candidaemia, with C. albicans as the predominant
fungal pathogen [7,8,14].
Thus, despite a general trend towards increased
rates of isolation of non-albicans Candida spp., the
frequency of isolation and the relative proportion
of C. albicans to non-albicans Candida spp. are
highly divergent in different European countries
and hospitals. The present study contributes to
current knowledge by describing a retrospective
survey of candidaemia that was performed during
2001–2006 at the University Hospital of Vienna,
Austria, a tertiary-care ⁄ teaching university hospi-
tal, which also functions as a primary-care centre
for the surrounding regions. The study also analy-
sed the overall consumption of antifungal agents
during the period 2001–2005.
MATERIALS AND METHODS
Setting
The University Hospital (Allgemeines Krankenhaus) Vienna is
a 2200-bed hospital that includes a large transplantation centre
and a haematology–oncology unit. The hospital also provides
intensive care and emergency medicine ⁄ surgery for the north-
east of Austria. Overall, the surgical departments perform
c. 45 000–50 000 procedures annually. This descriptive
retrospective study analysed blood cultures taken between
1 January 2001 and 31 December 2006 at the University
Hospital of Vienna. The number of annual admissions ranged
from 90 172 in 2001 to 94 421 in 2005, with no signiﬁcant
variation during the period of the study. Similarly, the number
of patients admitted annually to the haematology–oncology
unit, as well as to the intensive care unit (ICU), did not change
signiﬁcantly during the study period.
Microbiological procedures and antifungal agents
Blood cultures are taken routinely when patients deteriorate
and ⁄or have fever. The number of blood cultures processed
annually by the medical microbiology laboratory remained
stable during the 6-year period. During 2001–2002, an auto-
mated VITAL blood culture system (bioMe´rieux, Marcy
l’Etoile, France), including an aerobic and an anaerobic bottle,
was used. In March 2003, this system was replaced by the
BacTAlert blood culture system (bioMe´rieux), including an
aerobic and an anaerobic bottle containing the FAN-Medium,
with both blood culture systems run in parallel for 4 weeks.
No special media for fungal blood cultures were used. Blood
culture bottles positive for yeasts following a Gram’s stain
were plated on Chromagar Candida (Becton Dickinson,
Heidelberg, Germany) and incubated for 20–24 h at 35C.
Identiﬁcation of Candida isolates was performed using Chro-
magar Candida and rice extract agar, and further species
identiﬁcation was performed using the API 32 ID Candida
system (bioMe´rieux).
Data concerning the consumption of antifungal agents were
extracted from the hospital pharmacy computer system.
Antifungal agents were categorised using the Anatomical
Therapeutic Chemical classiﬁcation index with 2005 WHO
deﬁned daily doses (DDDs) (http://www.whocc.no/atcddd/
indexdatabase). The antifungal drugs evaluated were indi-
cated for either prophylaxis or curative treatment of fungal
infections, and comprised amphotericin B, amphotericin B
lipid complex, liposomal amphotericin B, 5-ﬂuorocytosine,
caspofungin, voriconazole, itraconazole and ﬂuconazole. Data
were collected for agents in Anatomical Therapeutic Chemical
group J02A, i.e., antifungal agents for systemic use. According
to the WHO database, the DDDs for the individual antifungal
agents were as follows: amphotericin B, 35 mg; 5-ﬂucytosine,
10 g; ﬂuconazole, 200 mg; itraconazole, 200 mg; voriconazole,
400 mg; and caspofungin, 50 mg.
Statistical analysis
The blood culture data contained in the Department of Medical
Microbiology computer were analysed using the MONI
program developed by the Institute for Computer Science of
the Medical University of Vienna. Each pathogen was counted
only once per patient within a 3-month period. The data were
analysed further using SPSS v.13.0 (SPSS Inc., Chicago, IL,
USA). Annual consumption of antifungal drugs was deter-
mined from pharmacy data. These data take into account all
hospital services using the drug, with any eventual returns of
the product deducted. The chi-square test was used to
compare the difference in the occurrence of C. albicans and
non-albicans Candida spp. among the different specialties.
Linear regression analysis was used to calculate the overall
increase in Candida spp., non-albicans Candida spp. and the use
of antifungal agents. Spearman rank correlations were used to
correlate the overall rate of Candida spp. or non-albicans
Candida spp. and the consumption of antifungal agents, with
p values <0.05 considered to be signiﬁcant.
RESULTS
Isolation of Candida spp.
The frequency of isolation of Candida spp. from
blood increased signiﬁcantly between 2001 and
2006, with the frequency (year) being 0.27 (2001),
0.40 (2002), 0.36 (2003), 0.64 (2004), 0.57 (2005) and
0.77 (2006) cases ⁄ 1000 admissions (p <0.005). The
incidence of candidaemia caused by C. albicans
and that caused by non-albicans Candida spp. both
rose during this period. Although C. albicans
remained the fungus isolated most frequently,
the emergence of non-albicans Candida spp.,
particularly C. glabrata and Candida parapsilosis,
was observed (Fig. 1). In general, the proportion
of blood cultures positive for Candida was as high
in medical wards (including haematology–oncol-
ogy, n = 103) as in ICUs (surgical plus medical
ICUs, n = 104), the surgical wards (n = 60) and
the neonatal ICU (n = 16). C. albicans (23 ⁄ 29 iso-
lates; 79%) remained the leading pathogen in the
haematology–oncology unit, followed by Candida
tropicalis and C. glabrata (2 ⁄ 29; 7% each), Candida
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sake and Candida lusitaniae (1 ⁄ 29; 3%, each).
Despite a trend towards an increased frequency
of non-albicans Candida spp. (37%), particularly
C. glabrata, in surgical wards, C. albicans remai-
ned the predominant pathogen (63%, p 0.067)
(Table 1).
The overall survival rate was 43.8%, ranging
from 32.8% in 2004 to 63.6% in 2002. In total, 108
(33.2%) patients died within 4 weeks of the ﬁrst
isolation of Candida spp. from blood, 58 (54%) of
these within the ﬁrst 7 days. A further 34 patients
died within the next 3 months after isolation of
Candida spp. from blood.
Consumption of antifungal agents
Consumption of antifungal agents increased con-
tinuously between 2001 and 2005 (p <0.005).
Fluconazole was the antifungal agent used most
frequently, followed by amphotericin B, and
consumption of all antifungal agents doubled
between 2002 and 2005. The overall increase in the
consumption of antifungal agents was explained
largely by an increased use of voriconazole and
caspofungin, while the consumption of ﬂucon-
azole and amphotericin B declined. When
analysed according to specialty units, ﬂuconazole
was used extensively in the surgical ICU during
2005 (7991.8 DDDs), followed by the haematolo-
gy–oncology unit (5121.8 DDDs), and other med-
ical (4172.5 DDDs) and surgical (3586.5 DDDs)
wards. Amphotericin B was used most frequently
in the surgical ICUs (2671.6 DDDs), followed by
the haematology–oncology unit (1996.8 DDDs)
and the cardiothoracic ICU (1476.9 DDDs).
Voriconazole was used most frequently in the
haematology–oncology unit (1619 DDDs), fol-
lowed by the cardiothoracic ICU (1136 DDDs)
and the medical wards (784 DDDs). Caspofungin
was used particularly in the surgical ICUs
(849.6 DDDs), in the cardiothoracic ICU (501.6
DDDs) and in the haematology–oncology unit
(444.8 DDDs). Although there was no correlation
between the overall consumption of antifungal
agents and the incidence of candidaemia, there
was a correlation between the increase in non-
albicans Candida spp. and the consumption of
ﬂuconazole (p <0.05).
DISCUSSION
Despite stable numbers of patient admissions,
including to the ICUs, the solid organ transplant
units and the haematology–oncology unit, there
was a signiﬁcant increase in the number of cases
of candidaemia between 2001 and 2006. However,
candidaemia can only be regarded as a surrogate
marker for the overall burden of invasive Candida
infections, as only one-third of patients with
invasive fungal infection have candidaemia
[13,15].
The increase in the incidence of candidaemia
was caused by an increased frequency of both
C. albicans and non-albicans Candida spp. (Fig. 1).
A rise in non-albicans Candida spp. has been
described in several previous studies worldwide,
ﬁrst in the USA [13,16], and more recently in
Europe [12,17]. A Danish study of the incidence
of fungaemia revealed an increasing incidence of
C. albicans, representing 63% of the isolates,
Table 1. Candida spp. (n, %) isolated in different units
during the period of the survey
Species
Medical
wards Surgery
Surgical
ICU
Medical
ICU
Neonatal
ICU
Candida albicans 73 (70.2) 38 (63.3) 47 (68.1) 25 (71.4) 15 (93.8)
Candida glabrata 11 (10.6) 13 (21.7) 9 (13) 6 (17.1) –
Candida parapsilosis 6 (5.8) 8 (13.3) 6 (8.7) 2 (5.7) 1 (6.3)
Candida tropicalis 7 (6.7) 1 (1.7) 5 (7.2) 1 (2.9) –
Candida lusitaniae 3 (2.9) – 1 (1.4) – –
Candida krusei – – – – –
Candida pelliculosa 1 (1) – – – –
Candida utilis – – – 1 (2.9) –
Candida melibiosica 1 (1) – – – –
Candida sake 1 (1) – – – –
Unidentiﬁed Candida sp. – – 1 (1.4) – –
Total 103 (100) 60 (100) 69 (100) 35 (100) 16 (100)
ICU, intensive care unit.
Fig. 1. Number of isolates of Candida spp. during 2001–
2006.
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followed by C. glabrata. However, although an
overall decrease in susceptibility to azoles was
observed among the Candida isolates, intrinsi-
cally resistant C. krusei isolates are rare in
Denmark [18]. In contrast, in the haematolo-
gy–oncology units of a French university hospi-
tal, only 32% of isolates were C. albicans, with
most being C. glabrata, C. tropicalis and C. krusei,
which are species that are generally less sensitive
or resistant to azoles. A rise in the frequency of
non-albicans Candida spp. has been attributed to
the use of azole antifungal agents, particularly
ﬂuconazole prophylaxis at a dose of 200 mg [5].
In a multicentre study conducted by the Euro-
pean Confederation of Medical Mycology, non-
albicans Candida spp. represented 65.4% of all
isolates [17].
In the present study, C. albicans remained the
leading fungal pathogen in Vienna, and, in
contrast to the French study [5], the ratio of
non-albicans Candida spp. to C. albicans was
highest in the surgical wards, rather than the
haematology–oncology unit. Antifungal prophy-
laxis with azoles is not used routinely for patients
at risk in the University Hospital of Vienna, but is
given as prophylaxis to patients undergoing
induction chemotherapy for acute leukaemia or
bone marrow transplantation, and to those with
severe graft vs. host disease [19].
The use of azole antifungal agents, particularly
ﬂuconazole, has been implicated in the decreased
isolation rate of C. albicans and the increased
isolation rate of non-albicans Candida spp. in
numerous studies [5,11–14,17]. In the present
study, the increased incidence rate of non-albicans
Candida spp. correlated with the use of ﬂucon-
azole. This agent is the therapy of choice for
infections caused by C. albicans at the University
Hospital of Vienna, with its use being highest in
the surgical ICUs and wards. In this hospital,
ﬂuconazole has been used at a ‘high dose’
(‡400 mg ⁄day), but is more usually given at a
dose of 10–20 mg ⁄ kg (600–1200 mg) ⁄day [20,21].
For patients at increased risk of developing
invasive Candida infection, particularly those hos-
pitalised in ICUs or who have undergone major
surgical interventions, the diagnostic tools avail-
able are limited largely to blood cultures (occa-
sionally aspirates), and to surrogate markers
such as colonisation scores [22,23]. Thus, empiri-
cal and pre-emptive antifungal therapy is used
extensively. The overall increase in the use of
antifungal agents is clearly a reaction to the
increase in candidaemia and presumptive inva-
sive fungal infections.
In conclusion, the present data revealed a net
increase in the frequency of candidaemia during
the study period. This overall increase in candida-
emia,with its crudemortality rate of 54.2%, despite
the availability and extensive use of seven potent
antifungal agents, warrants a close examination of
the affected patients and a re-evaluation of the
associated risk-factors. Better tools for the diag-
nosis of invasive fungal infections, and guidelines
for the management of these infections and the
prudent but effective use of antifungal agents, are
needed urgently.
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